When: If golden cross preserved and 50 SMA defended

Then: Maintain position - structural thesis intact per 8/14/8/17/8/18/8/21 pattern

HOLD - preserve existing ABBV exposure, capture dividend, wait for clearer entry at $240-$244; trim below $252.76 on rising volume; require volume and disclosure validation above $267.47 to add

• Current price $261.72 is ~16% above 200-day moving average and ~$5 below 52-week high of $267.47, not a screaming buy setup
• 43% DCF gap is dangerous because DCF models in pharma are highly sensitive to inputs; market pricing via multiples is more reliable than spreadsheet projections
• MACD has fallen from 10.45 in early July to 3.31 today with negative histogram and signal line above MACD line—this is momentum objectively deteriorating, not noise
• June 26 institutional print of 52.6 million shares is real but occurred 2.5 months ago; August 4 low of $243.80 traded through that supposed floor
• Q2 FCF of $3.1 billion is already below the $4 billion recovery threshold, making the cash flow trigger live and material
• Adding aggressively on 2-3% weakness is position-sizing error dressed as thesis; discipline at 50 SMA ($252.76) protects capital
• Skyrizi EU Crohn's filing is positive but largely priced in; next material move requires consecutive quarterly sales beats
• IRA Medicare negotiation risk for 2027 on Skyrizi, Rinvoq, and Imbruvica is real and unaccounted for
• ABBV underperformed healthcare peers over trailing year; defensive yield pharma is not where alpha is being generated in current regime
• Conservative position is about discipline, not absence of view—guardrails protect against 15% drops that happen regularly in pharma

→ vs aggressive: Forward P/E at 16x is treated as fact but forward earnings are estimates that can be revised lower; 16x can become 19-20x quickly on earnings miss or safety signal

→ vs aggressive: 43% DCF upside is only valid if discount rate, terminal growth, and FCF projections are correct—DCF in pharma is notoriously unreliable and sensitive to inputs

→ vs aggressive: MACD cooling is dismissed as noise but 10.45 to 3.31 over two months with negative histogram is objective momentum deterioration, not narrative

→ vs aggressive: June 26 institutional footprint of 52.6 million shares occurred 2.5 months ago; August 4 traded to $243.80, proving the floor thesis is more nuanced

→ vs aggressive: Adding aggressively on 2-3% weakness ($250-255) is position-sizing error; trim trigger at $252.76 should be respected, not dismissed as too tight

→ vs aggressive: Q2 FCF of $3.1 billion is below the $4 billion threshold, meaning the trigger is already live—not irrelevant as characterized

→ vs aggressive: Skyrizi EU Crohn's catalyst is largely priced in; market needs actual quarterly sales beats to re-rate, not regulatory filings already covered by Zacks and Simply Wall St.

→ vs aggressive: IRA Medicare negotiation risk for 2027 on Skyrizi, Rinvoq, Imbruvica is not in the bull case calculus at all

→ vs aggressive: Stable-rate regime actually favors rotation toward higher-beta growth (LLY up on M&A, MRK up 85% on pipeline), not defensive yield names—ABBV underperformed peers on trailing basis

Hold existing position, add in the $252-$256 confluence zone on pullbacks, trim on close below 50 SMA with hard stop at $247, maintain 1.5-2% portfolio weight

• Forward P/E of 16× with PEG of 0.37 is attractive, but consensus EPS of $16.28 represents ~5× jump from TTM EPS of $3.54 due to Allergan integration amortization and one-time charges
• TTM P/E of 73.9 versus forward of 16.1 shows market has only partially priced earnings normalization, creating room for multiple expansion or disappointment
• MACD at 3.31 with signal at 3.45 and histogram of negative 0.14 represents a yellow flag, not a red flag—controlled digestion rather than breakdown
• June 26 institutional accumulation of 52.6 million shares creates structural support around $240-$250 zone, not an impenetrable floor
• Q2 FCF of $3.1 billion against $3 billion dividends (71% coverage) needs Q3 confirmation; if FCF recovers to $4 billion-plus the conservative thesis is dead
• IRA Medicare negotiation risk for 2027 on Skyrizi, Rinvoq, and Imbruvica represents a real but probability-weighted structural overhang
• EU Skyrizi Crohn's filing is a small positive catalyst that supports but does not change the existing thesis
• Add zone tightened to $252-$256 based on rising 50 SMA at $252.76 and Bollinger middle at $255.74—confluence zone actually tested multiple times
• Trim trigger: close below rising 50 SMA on rising volume as first warning, with deeper hard stop at $247 (approximately 2× ATR below 50 SMA)
• Position sizing of 1.5 to 2% portfolio weight recommended given defensive sector, low beta of 0.28, and 2.66% yield

→ vs aggressive: Overconfident in asymmetric upside; underweights real risks like IRA Medicare negotiation exposure for Skyrizi/Rinvoq/Imbruvica and execution dependencies; treats forward normalization as one-way bet when there's real tail risk in both directions

→ vs aggressive: Proposed $250-$255 add zone is too aggressive by roughly the same magnitude as the trader's overly conservative $240-$244 zone; gets a 7-8.5% pullback in a low-beta stock (0.28) requires meaningful shift in fundamentals or sector dynamics that may not occur

→ vs aggressive: Argument to add aggressively on a 50 SMA break is genuinely dangerous risk management; when the 50 SMA breaks, something has changed and the right move is to trim, not add

→ vs conservative: Overplays the bear case and underweights the genuinely attractive forward valuation setup with PEG of 0.37 and partial earnings normalization not yet priced in

→ vs conservative: Implicit faith in market efficiency breaks down in practice; markets systematically misprice mean-reverting assets and momentum in pharma can reverse violently on pipeline events

→ vs conservative: IRA risk is in the data but not being weighted properly; treating it as non-factor understates structural overhang on three most important growth assets

→ vs conservative: Skyrizi EU Crohn's catalyst dismissed too aggressively; it's a real catalyst that extends franchise and improves commercial positioning versus IV-infused competitors